PLX Related Analyst Ratings
-
Brazilian Approval a Positive for Protalix (PLX) - Oppenheimer
-
Jefferies Starts Protalix BioTherapeutics (PLX) at Hold; Key Driver = Elelyso Commercial Success
-
Canaccord Genuity Reiterates Hold on Protalix BioTherapeutics (PLX)
-
Canaccord Genuity Reiterates a 'Hold' on Protalix BioTherapeutics (PLX); Modest U.S. But Strong In Israel
-
Wells Fargo Downgrades Protalix (PLX) to Market Perform
-
Aegis Starts SGYP, IRWD, AMRN, MDVN at Buy, PLX at Hold
-
Auriga Reiterates a 'Buy' on Protalix BioTherapeutics (PLX); Eyes on Elelyso launch in U.S.
-
Auriga Upgrades Protalix BioTherapeutics (PLX) to Buy
-
UPDATE - Canaccord Genuity Downgraded Protalix BioTherapeutics (PLX) to Hold; Taking A Good Look
-
Canaccord Genuity Downgrades Protalix BioTherapeutics (PLX) to Hold
-
UPDATE - Auriga Downgraded Protalix BioTherapeutics (PLX) to Hold; Odds of FDA Approval Are Difficult to Gauge
-
Auriga Downgrades Protalix BioTherapeutics (PLX) to Hold
-
Canaccord Genuity Reiterates a 'Buy' on Protalix BioTherapeutics (PLX); U.S. Tali Approval May Unlock Potential
-
Auriga Reiterate a 'Buy' on Protalix BioTherapeutics (PLX); No Material Changes in 10-K
-
Canaccord Genuity Reiterates a 'Buy' on Protalix BioTherapeutics (PLX); WORLD 2012: Tali Safety Detail Continues to Support Approval
-
Canaccord Genuity on Life Sciences/Biotechnology: Forex Exposure - Impact ITMN, PLX, AEGR & ONXX
-
Wells Fargo Cuts Valuation Range on Protalix BioTherapeutics (PLX), Comments on Taliglucerase Delay
-
Auriga Starts Protalix BioTherapeutics (PLX) at Buy
-
Canaccord Genuity Reiterates a 'Buy' on Protalix BioTherapeutics (PLX); Q3/11: Tali NDA on Track, Cerezyme Shortage Continues
-
Canaccord Genuity Reiterates a 'Buy' on Protalix BioTherapeutics (PLX); Tali FDA Approval on Track for Feb'12
-
Canaccord Genuity on Life Sciences/Biotechnology: FDA �Flexibility� May Add To Advantages of Orphan Drugs in Today's Market
-
Morgan Joseph Starts Protalix BioTherapeutics (PLX) at Hold
-
Canaccord Genuity Reiterates a 'Buy' on Protalix BioTherapeutics (PLX); New Tali PDUFA: Feb. 2012; EU Approval on Track for Q2/12
-
Canaccord Genuity Reiterates a 'Buy' on Protalix BioTherapeutics (PLX); Resubmission Soon: FDA Focus on Full Switch Data, Not CMC
-
Hapoalim Securities Upgrades Protalix BioTherapeutics (PLX) to Hold
-
Canaccord Genuity Reiterates a 'Buy' on Protalix BioTherapeutics (PLX); Q1/11: Positive FDA Meeting, PLX to Resubmit Tali in Mid-2011
-
WBB Securities Downgrades Protalix BioTherapeutics (PLX) to Buy
-
Get Your Due Diligence On: Likely Russell 2000 Additions and Deletions
-
Capstone Downgrades Protalix (PLX), Salix (SLXP) to Hold
-
Hapoalim Cuts Protalix (PLX) from Buy to Sell, Reduces Price Target to $6
-
Noble Financial Downgrades Protalix BioTherapeutics (PLX) to Hold; Taliglucerase Alfa Receives Complete Response Letter
-
Canaccord Adams Sees Protalix BioTherapeutics (PLX) FDA Approval Early
-
Canaccord Genuity Reiterates a 'Buy' on Protalix BioTherapeutics (PLX); Expect Tali Data at WORLD to Back Approval, Clean Label
-
Protalix BioTherapeutics (PLX) Smacked On UBS Intra-Day Downgrade
-
Protalix (PLX) Falls On Downgrade
-
Protalix BioTherapeutics (PLX) Rebounds On Path to FDA Approval
-
Canaccord Genuity Reiterates a 'Buy' on Protalix BioTherapeutics (PLX); Predict Timely US Approval on PDUFA
-
Wells Fargo Starts Protalix BioTherapeutics (PLX) at Outperform; Attractive Platform
-
Canaccord Genuity Reiterates a 'Buy' on Protalix BioTherapeutics (PLX); EU Approval Application In: tali EMEA OK Possible By Early 2012
-
UBS Maintains a 'Buy' on Protalix (PLX); Capture Brazilian Gaucher Market
-
CapStone Upgrades Protalix (PLX) to Strong Buy; Calls Taliglucerase Alfa News a Positive
-
Canaccord Genuity maintains a 'Buy' on Protalix BioTherapeutics (PLX); PLX-105 Moves Ahead, More Proof of Concept for Platform
-
Canaccord Genuity Maintains a 'Buy' on Protalix BioTherapeutics (PLX); CMC Headline Risk May Not Impact Approvability
-
Capstone Investments Initiates Coverage on Protalix BioTherapeutics (PLX) with a Buy
-
Hapoalim Securities Initiates Coverage on Genzyme (GENZ) with a Hold; Pipeline Promising, But Near-Term Competition
-
Hapoalim Securities Reiterates a 'Buy' on Protalix (PLX); Raises PT in Wake of Pfizer (PFE) Deal
-
Canaccord Adams Maintains a 'Buy' on Protalix BioTherapeutics (PLX); Cerezyme Supply on Track, See More Uplyso EAP Uptake
-
Canaccord Adams Reiterates a 'Buy' on Protalix BioTherapeutics (PLX)
-
Canaccord Adams Starts Protalix BioTherapeutics (PLX) at Buy
-
Hapoalim Securities Initiates Coverage on Protalix BioTherapeutics (PLX) with an Outperform; Attractive Entry Point
Back to PLX Stock Lookup
